Neurocognitive Disorders Clinical Trial
— Neuro-H2OilOfficial title:
Evaluating the Long-term Neurocognitive Effects of Preconceptional Exposure to Iodinated Contrast During Hysterosalpingography (HSG) on the Offspring of the H2Oil Trial
Verified date | January 2022 |
Source | VU University Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Iodinated contrast is commonly used in hysterosalpingography (HSG), a diagnostic tool in fertility work-up. This study aims to investigate the safety of contrast media used during HSG by evaluating the long-term effects on the neurodevelopment of offspring 6-8 years after exposure to iodinated contrast media.
Status | Active, not recruiting |
Enrollment | 64 |
Est. completion date | August 1, 2022 |
Est. primary completion date | July 1, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 5 Years to 10 Years |
Eligibility | Inclusion Criteria: - Children conceived after the mother underwent HSG procedure in the context of the H2Oil trial (2012-2014) - Children must be conceived <6 months after the HSG procedure - Parents must have given consent for recontacting for follow up research Exclusion Criteria: - Children conceived after the mother underwent HSG procedure that was not part of the H2Oil trial - Children conceived >6 months after the HSG procedure - Children whose parents did not give permission to be recontacted for follow up research - Children that are not able to comprehend the instructions at the time of assessment - Absence or withdrawal of written informed consent - Inability to comprehend testing instructions at time of assessment - Severe motor disability that interferes with outcome assessment at time of assessment - Documented and/or parent-reported diagnosis of a neurological disorder - Somatic disorders known to affect the outcome assessments at time of assessment |
Country | Name | City | State |
---|---|---|---|
Netherlands | Emma Kinderziekenhuis | Amsterdam | Noord-Holland |
Lead Sponsor | Collaborator |
---|---|
VU University Medical Center | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
Netherlands,
Dreyer K, van Rijswijk J, Mijatovic V, Goddijn M, Verhoeve HR, van Rooij IAJ, Hoek A, Bourdrez P, Nap AW, Rijnsaardt-Lukassen HGM, Timmerman CCM, Kaplan M, Hooker AB, Gijsen AP, van Golde R, van Heteren CF, Sluijmer AV, de Bruin JP, Smeenk JMJ, de Boer JAM, Scheenjes E, Duijn AEJ, Mozes A, Pelinck MJ, Traas MAF, van Hooff MHA, van Unnik GA, de Koning CH, van Geloven N, Twisk JWR, Hompes PGA, Mol BWJ. Oil-Based or Water-Based Contrast for Hysterosalpingography in Infertile Women. N Engl J Med. 2017 May 25;376(21):2043-2052. doi: 10.1056/NEJMoa1612337. Epub 2017 May 18. — View Citation
Königs M, Verhoog EM, Oosterlaan J. Exploring the neurocognome: Neurocognitive network organization in healthy young adults. Cortex. 2021 Oct;143:12-28. doi: 10.1016/j.cortex.2021.06.011. Epub 2021 Jul 14. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | School performance | Longitudinal data on school performance will be collected using standardised tests from the pupil monitoring system developed by the Dutch National Institute for Educational Measurement (CITO-test). CITO-tests are used to assess children's academic performance (reading comprehension, spelling, and arithmetic performance) in primary schools in the Netherlands. | Between the ages of 4-12, up to 12 years | |
Primary | Intelligence | General intelligence will be assessed using a shortened Fifth version of the Wechsler Intelligence Scale for Children. Full-scale IQ (FSIQ) will be estimated using the subtests Vocabulary, Similarities, Matrix Reasoning, and Block Design. | 1 Day | |
Primary | Behavioural functioning evaluated through the Strengths and Difficulties Questionnaire (SDQ). | Behavioural functioning will be evaluated through the Strengths and Difficulties Questionnaire (SDQ). Both parents and teachers will fill in the SDQ. | 1 Day | |
Primary | Behavioural functioning evaluated through the Strengths and Weaknesses of ADHD Symptoms And Normal behaviour (SWAN) scale. | Behavioural functioning will be evaluated will be evaluated using the Strengths and Weaknesses of ADHD Symptoms And Normal behaviour (SWAN) scale. Both parents and teachers will fill in the SWAN scale. | 1 Day | |
Secondary | Visuomotor integration | Visuomotor integration will be assessed using a Track & Trace task of the Emma Toolbox for Neurocognitive Functioning, which is an in-house designed battery of computerised tests for assessing different neurocognitive domains. | 1 Day | |
Secondary | Processing & Control | Processing & Control will be assessed using an Attention Network Test of the Emma Toolbox for Neurocognitive Functioning, which is an in-house designed battery of computerised tests for assessing different neurocognitive domains. | 1 Day | |
Secondary | Visual Memory | Visual Memory will be assessed using an Location Learning Test of the Emma Toolbox for Neurocognitive Functioning, which is an in-house designed battery of computerised tests for assessing different neurocognitive domains. | 1 Day | |
Secondary | Verbal Memory | Verbal Memory will be assessed using a Rey Auditory Verbal Learning Test (Dutch Version) of the Emma Toolbox for Neurocognitive Functioning, which is an in-house designed battery of computerised tests for assessing different neurocognitive domains. | 1 Day | |
Secondary | Visual Working Memory | Visual Working Memory will be assessed using a Klinberg task of the Emma Toolbox for Neurocognitive Functioning, which is an in-house designed battery of computerised tests for assessing different neurocognitive domains. | 1 Day | |
Secondary | Verbal Working Memory | Verbal Working Memory will be assessed using a Digit Span task of the Emma Toolbox for Neurocognitive Functioning, which is an in-house designed battery of computerised tests for assessing different neurocognitive domains. | 1 Day |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05754567 -
CONCEPTT Kids International Neurodevelopmental Outcomes Among Offspring of Women With Type 1 Diabetes
|
||
Completed |
NCT05080777 -
Pilot Pragmatic Clinical Trial to Embed Tele-Savvy Into Health Care Systems
|
N/A | |
Not yet recruiting |
NCT03276377 -
VItamin K Inhibition and NeurocoGnition (VIKING)
|
N/A | |
Completed |
NCT04175223 -
Impact of Probiotics in HIV-positive Patients With Neurocognitive Disorders
|
N/A | |
Completed |
NCT03538522 -
A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831
|
Phase 2 | |
Recruiting |
NCT05732285 -
A Pilot Randomized Controlled Trial: CoINTEGRATE
|
N/A | |
Recruiting |
NCT04095962 -
Effects of a Multicomponent Exercise Intervention on Physical and Cognitive Function of Older Adults With Dementia
|
N/A | |
Not yet recruiting |
NCT04113577 -
COgilus Remediation in Alzheimer Patients (CORA)
|
||
Recruiting |
NCT06320639 -
DRIVing Simulator and People With NeuroCognitive Disorders
|
||
Recruiting |
NCT06105320 -
COGNIFOOD-Changing the Carbohydrate/Fat-ratio to Prevent Cognitive Decline and Alzheimer Pathology: A Pilot Study
|
N/A | |
Completed |
NCT03050385 -
Cognitive Rehabilitation During Transcranial Direct Current Stimulation
|
N/A | |
Active, not recruiting |
NCT06372002 -
Effectiveness and Cost-Effectiveness of Cognitive Stimulation Therapy - Spain (CST-ES) in People Living With Dementia
|
N/A | |
Recruiting |
NCT05508789 -
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
|
Phase 3 | |
Recruiting |
NCT03926351 -
High Dose Omega 3 in People at Risk for Dementia
|
Phase 2 | |
Recruiting |
NCT05504681 -
Integration of Neurocognitive Biomarkers Into a Neuro-Oncology Clinic
|
||
Completed |
NCT04168268 -
Patient-reported Outcome Measures After Post-anesthesia Care Unit Delirium
|
||
Recruiting |
NCT04825847 -
Neurocognitive Disorders After Major Surgery in Elderly
|
N/A | |
Active, not recruiting |
NCT02958670 -
Imaging Tau Deposition in the Brain of Elderly Subjects
|
N/A | |
Enrolling by invitation |
NCT02652598 -
Evaluate the Effects of Tolcapone on Cognitive and Behavioral Dysfunction in Patients With BI and NCD
|
Phase 2 | |
Completed |
NCT02825732 -
MEMORA-Caregiver : Risk Factors of Caregiver Burden Among Patients With Neurocognitive Disorders or Subjective Cognitive Complaint
|
N/A |